Singapore, Aug. 18 -- LEO Pharma, a global leader in medical dermatology delivering innovative solutions for skin disease, has entered into an agreement to acquire worldwide rights to dersimelagon from Japan-based Tanabe Pharma. Dersimelagon is an oral, once-daily small MC1R agonist being developed for erythropoietic protoporphyria (EPP) and X-linked proto-porphyria (XLP).

EPP and XLP are rare and severe genetic diseases that cause severe sunlight-induced skin damage and can significantly limit patients' ability to spend time outdoors.

The acquisition reflects LEO Pharma's strategy to continue to strengthen its medical dermatology portfolio through targeted partnerships, acquisitions, and external innovation, with rare dermatology as a ...